Navigation Links
ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
Date:8/5/2009

HALIFAX, NS, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with UK-based Scancell Ltd., the operating company of Scancell Holdings Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT's DepoVax(TM) delivery system for Scancell's novel ImmunoBody(R) DNA vaccines.

"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax(TM) technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."

"IVT's DepoVax(TM) represents a potentially attractive future delivery system for our ImmunoBody(R) DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.

DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines

DepoVax(TM) is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax(TM) enhances the immunogenicity of antigens in general, and can be used to dramatically enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax(TM) amenable to commercialization.

ImmunoVaccine Technologies continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary vaccine delivery technology for two livestock vaccines. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defence Research Development Canada, FIT Biotech, and Immunotope Inc. the value of Depovax(TM) has been significantly enhanced. www.immunovaccine.com.

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody(R) technology platform. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and will enter clinical trials using electroporation technology in early 2010.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.


'/>"/>
SOURCE IMMUNOVACCINE TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
11. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... WEDI, the nation’s ... exchange, today announced that Charles W. Stellar has been named by the WEDI Board ... since January 2016. As an executive leader with more than 35 years of experience ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth ... held The Future of San Diego Life Science event at the Estancia La Jolla ... attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary Medicine Company, ... veterinary clients have treated over 100 of their own patients with the VetStem Cell ... highest level of care for their patients. , The veterinarians are Dr Ross ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):